Average Ratings 0 Ratings
Average Ratings 0 Ratings
Description
AarogyaAI is a software-as-a-service platform that utilizes artificial intelligence to identify drug-resistant tuberculosis (DR-TB) within hours. Our goal is to provide rapid and precise diagnoses of DR-TB, ensuring that patients receive the most effective drug combinations for their treatment without delay. Tuberculosis is responsible for more fatalities annually than AIDS, largely because the 19 available anti-TB medications do not work for all patients, leading to uncertainty among doctors regarding the appropriate treatment options. Consequently, even though tuberculosis is treatable, a delayed diagnosis of drug-resistant forms can result in patients remaining on ineffective medications for as long as seven years. By diagnosing drug-resistant tuberculosis swiftly, we enable prompt and appropriate treatment prescriptions. Patients upload a DNA sequence to our platform, and our advanced machine learning algorithm processes this data to generate a detailed report on drug susceptibility status, allowing healthcare providers to make informed decisions about treatment. This innovative approach not only enhances patient outcomes but also aims to reduce the overall burden of tuberculosis on healthcare systems.
Description
Our innovative AI engine is revolutionizing the drug discovery process, enabling the creation of superior medications at an accelerated pace. The breakthroughs we achieve contribute to the development of medicines more efficiently and effectively. Our portfolio of AI-driven discoveries encompasses entirely owned and collaboratively developed pipeline assets, supported by leading investors in the industry. Atomwise has engineered a cutting-edge machine-learning discovery platform that merges the capabilities of convolutional neural networks with extensive chemical libraries to identify new small-molecule treatments. The key to transforming drug discovery through AI lies in our talented team. We are committed to enhancing our AI platform and leveraging it to revolutionize the discovery of small molecule drugs. It is essential that we confront the most daunting and seemingly insurmountable targets, streamlining the entire drug discovery process to provide developers with increased opportunities for success. Enhanced computational efficiency allows us to screen trillions of compounds virtually, significantly boosting the chances of finding viable solutions. Our impressive model accuracy has successfully addressed the persistent issue of false positives, underscoring the reliability of our approach. Ultimately, our dedication to innovation and excellence sets us apart in the quest for breakthrough therapies.
API Access
Has API
No
API Access
Has API
No
Integrations
No details available.
Integrations
No details available.
Pricing Details
No price information available.
Free Trial
No
Free Version
No
Pricing Details
No price information available.
Free Trial
No
Free Version
No
Deployment
Web-Based
Yes
On-Premises
No
iPhone App
No
iPad App
No
Android App
No
Windows
No
Mac
No
Linux
No
Chromebook
No
Deployment
Web-Based
Yes
On-Premises
No
iPhone App
No
iPad App
No
Android App
No
Windows
No
Mac
No
Linux
No
Chromebook
No
Customer Support
Business Hours
No
Live Rep (24/7)
No
Online Support
Yes
Customer Support
Business Hours
No
Live Rep (24/7)
No
Online Support
Yes
Types of Training
Training Docs
No
Webinars
No
Live Training (Online)
No
In Person
No
Types of Training
Training Docs
Yes
Webinars
Yes
Live Training (Online)
No
In Person
Yes
Vendor Details
Company Name
AarogyaAI
Country
India
Website
aarogya.ai/
Vendor Details
Company Name
Atomwise
Founded
2012
Country
United States
Website
www.atomwise.com